The goal of this study is to evaluate whether MYTP01, a traditional Chinese herbal formula developed by clinical experts with the assistance of artificial intelligence (AI), is effective and safe as an additional treatment for immune-mediated diseases (post-kidney transplantation, IgA nephropathy, etc.). The study also aims to explore whether MYTP01 may provide therapeutic benefits across these conditions by regulating shared immune and inflammatory processes. The main questions this study aims to answer are:
* Does MYTP01 provide clinical benefits and remain safe when used as an additional treatment for immune-mediated conditions?
* Does MYTP01 help regulate immune balance and inflammatory responses across immune-mediated disease populations?
Researchers will compare MYTP01 with a matching placebo, with both treatments given in addition to standard medical care, to evaluate clinical efficacy, safety, and potential immunomodulatory effects across immune-mediated conditions.
Participants will:
* Be enrolled in a disease-specific cohort based on their clinical condition.
* Be randomly assigned to receive either MYTP01 or placebo in addition to their usual medical treatment.
* Take the assigned study treatment twice daily for 8 weeks.
* Attend follow-up visits approximately once a month during a 12-week study period.
* Undergo clinical assessments, blood and urine tests, and evaluations of immune function and possible side effects.